Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
Celldex Therapeutics (Nasdaq: CLDX) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 2:20 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celldex Therapeutics (Nasdaq: CLDX) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 2:20 p.m. ET. A webcast will be accessible on the 'Events & Presentations' page of the company’s website, with a replay available for 14 days post-event.
Celldex is focused on developing monoclonal and bispecific antibodies to treat serious diseases, aiming to enhance the lives of patients suffering from inflammatory diseases and various cancers.
Details
News Market Reaction – CLDX
The recorded move for CLDX in the trading session of this news was +1.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET.
A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for fourteen days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.